Effect of Cilostazol on vascular endothelial function in type 2 diabetic patients with peripheral arterial disease

Effect of Cilostazol on vascular endothelial function in type 2 diabetic patients with peripheral arterial disease - Effect of Cilostazol on vascular endothelial function in type 2 diabetic patients with peripheral arterial disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003994

Enrollment

Registered

2010-08-05

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Peripheral arterial disease

Interventions

Cilostazol 50-100mg X 2 / day 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes 2. Toe brachial pressure index < 0.6 3. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Active bleeding or bleedind tendency 2. Congestive heart failure 3. History of hypersensitivity to Cilostazol 4. Pregnancy 5. Severe hepatic or renal dysfunction 6. Uncontrolled proliferative retinopathy 7. Malignancy 8. Patients ineligible for the study determined by doctors

Design outcomes

Primary

Measure	Time frame
Flow-mediated vasodilatation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026